drugset / Trial / NCT00915174

Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects

NCT00915174 ↗

Phase 1 Completed 36 enrolled Merz Pharmaceuticals GmbH
RandomizedCrossoverDouble-blind

Summary

Primary: To assess the effects of repeated dose of Neramexane on the steady-state pharmacokinetics of Drospirenone \[DRSP\] and Ethinyl Estradiol \[EE\] Secondary: To assess safety and tolerability of concomitant repeated dose treatments of Neramexane and a fixed-combinational DRSP- and EE-containing oral contraceptive \[OC\] (Yasmin®)

Timeline

Start
2009-06
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Neramexane Small molecule 50 mg —

Indications

No indication recorded.